Načítá se...
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side e...
Uloženo v:
| Vydáno v: | Case Rep Med |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5698793/ https://ncbi.nlm.nih.gov/pubmed/29250117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/5264216 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|